

Enrolled
(N=43)

Safety population/
mITT population
(n=43)

Placebo
(n=12)

VX-509 100 mg
(n=11)

VX-509 200 mg*
(n=10)

VX-509 300 mg
(n=10)

Discontinued (n=1)
Refused further
dosing (not
due to AEs) (n=1)

Discontinued (n=1)
Lost to
follow-up (n=1)

Discontinued (n=1)

Discontinued (n=2)
Adverse event (n=2)

Completed dosing
(n=11)

Completed dosing
(n=10)

Completed dosing
(n=10)

Completed dosing
(n=8)